Literature DB >> 15831640

Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study.

D A Stakos1, D P Schuster, E A Sparks, C F Wooley, K Osei, H Boudoulas.   

Abstract

OBJECTIVE: To study the long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance. PATIENTS: 181 African American subjects with insulin resistance and normal glucose tolerance test were randomised to receive glipizide 5 mg/day (n = 25), metformin 500 mg/day (n = 59), or placebo (n = 97) for 24 months. Insulin sensitivity, glucose tolerance, lipid profile, left ventricular mass (echocardiography), aortic distensibility (echocardiography, blood pressure), aortic pulse wave velocity (PWV, carotid to femoral artery, Doppler) were measured at baseline and at 12 and 24 months after randomisation.
RESULTS: A significant increase in PWV was observed in both glipizide (mean (SEM) change at 24 months 2.8 (2.7) m/s, p = 0.012) and metformin (2.2 (0.7) m/s, p = 0.01) groups during the follow up period. In contrast, PWV remained unchanged in the placebo group. The increase in PWV in the treatment groups was significant compared with placebo (analysis of variance p < 0.05). Other cardiovascular or metabolic variables did not change significantly compared with placebo during follow up.
CONCLUSIONS: The observed increase in PWV is consistent with a decrease in the elastic properties of the aorta. The use of oral antidiabetic agents for the prevention of cardiovascular complications in non-diabetic African Americans with insulin resistance needs to be critically evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831640      PMCID: PMC1768883          DOI: 10.1136/hrt.2003.027722

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  29 in total

1.  Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.

Authors:  S Laurent; P Boutouyrie; R Asmar; I Gautier; B Laloux; L Guize; P Ducimetiere; A Benetos
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

2.  Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

Authors:  M A Charles; E Eschwège; P Grandmottet; F Isnard; J M Cohen; J L Bensoussan; H Berche; O Chapiro; P André; P Vague; I Juhan-Vague; J M Bard; M Safar
Journal:  Diabetes Metab Res Rev       Date:  2000 Jan-Feb       Impact factor: 4.876

3.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

5.  Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study.

Authors:  Pierre Boutouyrie; Anne Isabelle Tropeano; Roland Asmar; Isabelle Gautier; Athanase Benetos; Patrick Lacolley; Stéphane Laurent
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

6.  Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?

Authors:  Kennedy Cruickshank; Lisa Riste; Simon G Anderson; John S Wright; Graham Dunn; Ray G Gosling
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

7.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield
Journal:  Arch Intern Med       Date:  2003-02-24

8.  Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years.

Authors:  Timo E Strandberg; Veikko V Salomaa; Hannu T Vanhanen; Kaisu Pitkälä; Tatu A Miettinen
Journal:  J Hypertens       Date:  2002-03       Impact factor: 4.844

9.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

10.  Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.

Authors:  Kwame Osei; Scott Rhinesmith; Trudy Gaillard; Dara Schuster
Journal:  Metabolism       Date:  2003-05       Impact factor: 8.694

View more
  7 in total

1.  Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.

Authors:  Fuhai Hui; Yingshi Zhang; Tianshu Ren; Xiang Li; Mingyi Zhao; Qingchun Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-12-03       Impact factor: 2.953

2.  Regional and overall aortic function in nondiabetic individuals with insulin resistance and normal glucose tolerance.

Authors:  Dimitrios A Stakos; Konstantinos D Boudoulas; Trudy R Gaillard; Dara P Schuster; Kwame Osei; Harisios Boudoulas
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

3.  Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials.

Authors:  Shuwei Weng; Yonghong Luo; Ziyu Zhang; Xin Su; Daoquan Peng
Journal:  Endocrine       Date:  2020-01-16       Impact factor: 3.633

4.  Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study.

Authors:  Nanna B Johansen; Morten Charles; Dorte Vistisen; Signe S Rasmussen; Niels Wiinberg; Knut Borch-Johnsen; Torsten Lauritzen; Annelli Sandbæk; Daniel R Witte
Journal:  Diabetes Care       Date:  2012-07-11       Impact factor: 19.112

5.  Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.

Authors:  Helena Atroch Machado; Marcelo Vieira; Maria Rosaria Cunha; Marcia Regina Soares Correia; Rosa Tsunechiro Fukui; Rosa Ferreira dos Santos; Dalva Marreiro Rocha; Bernardo Leo Wajchenberg; Silvia G Lage; Maria Elizabeth Rossi da Silva
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

6.  Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes.

Authors:  José E Rodríguez; Kendall M Campbell
Journal:  Clin Diabetes       Date:  2017-01

7.  Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials.

Authors:  Ahmed M Kamel; Nirmeen Sabry; Samar Farid
Journal:  BMC Cardiovasc Disord       Date:  2022-09-10       Impact factor: 2.174

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.